▷ Sartorius Dividends 【Calendar 2024】

Upcoming Sartorius dividend

Change(%)

-48.95%

Decrease

Next payment 0.73€

Next payment date Apr 4, 2024

Last payment 1.43€

Last payment date Apr 3, 2023

00 D 00 H 00 M 00 S

Ex-Dividend: 4/2/24

Confirmed

When are the upcoming Sartorius dividends in 2024?

▶

Holders of shares in Sartorius will enjoy a dividend of 0,73 euros per share with a yield of 0.40% on April 4, 2024.

What is the last day to buy Sartorius stocks and get dividends?

▶

To receive a dividend of 0,73 euros from Sartorius, purchase the shares before April 2, 2024 and stay until the Record Date, April 3, 2024.

Last Sartorius dividend

▶

Sartorius made a dividend payment of 1.43 euros on April 3, 2023.

Dividend policy of Sartorius

▶

Sartorius AG, which is listed on the German and Austrian stock exchanges using the stock exchange indicator SRT, began paying dividends in 1999 and has been paying this interest continuously for more than twenty years.

The payment schedule is established by the stockholders' meeting, which approves the amount, being paid in a single installment between March and April, obtaining a yield of approximately 0.45%.

Payout Ratio Sartorius Dividends

Sartorius paid 6% of its net income in the last fiscal period as dividends.

Sartorius's earnings (3,323,699,968.00€) are sufficient to cover the dividend payment. This payment represents 6% of the total net profit of SRT.

Dividend payout ratio Payout Ratio

Dividend calendar of Sartorius

These are the most important events of the Sartorius calendar in 2024:

Event	Day
Last trading date	April 1, 2024
Ex-Dividend (Ex-Date)	April 2, 2024
Record date	April 3, 2024
Date of payment	April 4, 2024

Data confirmed by the company Sartorius (SRT).

Confirmed Source

Historical annual dividend yields of Sartorius

Over the past 5 years, Sartorius has not consistently increased the annual dividend amount.

Increasing Dividends Dividend yield

Dividend yield of Sartorius vs. the sector

Sartorius's dividend yield (0.40%) is below the sector average (1.87%).

Comparison with industry average

Sartorius's dividend yield is below the top 75% (0.52%) of the sector.

Evaluation with respect to competence.

Dividend yield history in Sartorius

Over the past 5 years, Sartorius's annual dividend income has fallen by more than 10%.

Dividend stability

Dividend history of Sartorius

In this table you can see the complete history:

Year	Ex-Dividend	Amount	Total
2023	03/30/2023	1.43 €	1.43 €
2022	03/28/2022	1.25 €	1.25 €
2021	03/29/2021	0.7 €	0.7 €
2020	06/29/2020 03/27/2020	0.35 € 0.7 €	1.05 €
2019	03/29/2019	0.61 €	0.61 €
2018	04/06/2018	0.5 €	0.5 €
2017	04/07/2017	0.45 €	0.45 €
2016	04/08/2016	0.375 €	0.375 €
2015	04/10/2015	0.265 €	0.265 €
2014	04/11/2014	0.25 €	0.25 €
2013	04/19/2013	0.235 €	0.235 €
2012	04/20/2012	0.2 €	0.2 €
2011	04/21/2011	0.15 €	0.15 €
2010	04/22/2010	0.073625 €	0.073625 €
2009	04/24/2009	0.1 €	0.1 €
2008	04/24/2008	0.165 €	0.165 €
2007	04/30/2007	0.155 €	0.155 €
2006	04/27/2006	0.125 €	0.125 €
2005	05/13/2005	0.1 €	0.1 €
2004	05/28/2004	0.06 €	0.06 €
2003	06/19/2003	0.06 €	0.06 €
2002	06/20/2002	0.06 €	0.06 €
2001	06/22/2001	0.06 €	0.06 €
2000	06/22/2000	0.06 €	0.06 €

Sartorius dividend capture strategy

Step 1: Buy Sartorius shares (SRT) one day before ex-dividend date

Date of purchase Apr 1, 2024

Next ex-dividend date Apr 2, 2024

Step 2: Sell Sartorius shares (SRT) when the price recovers.

Date of sale (estimated) N/A

Average price recovery N/A

Average return on cost N/A

The dividend capture strategy is based on historical Sartorius data. Past performance is no guarantee of future results.

Information about Sartorius

Full name Sartorius Aktiengesellschaft

Ticker SRT

Sector Health Care

Industry Medical Instruments & Supplies

Market Capitalization 14.16B €

ISIN DE0007165607

Number of Employees 15,942

Description of the company

Sartorius AG, an international company based in Germany, manufactures equipment and products for pharmaceutical laboratories.

Along the way, it has made several acquisitions as part of its growth strategy, including B. Braun Biotech International (BBI), Viva Science, Omnimark Instrument Corporation, Stedim SA, Toha Plast GmbH, Wave Biotech AG, the liquid handling business of Biohit Laboratory, kSep Systems, Essen BioScience, Xell AG and signed a co-development agreement with Nova Biomedical.

The company helps biotech engineers and scientists develop drugs to treat previously incurable diseases such as cancer and dementia by offering instruments, laboratory services, consumables and chemicals, water purification systems, fermentation solutions, fluid management, as well as software and training.

Its product portfolio includes Bioreactors, Fermenters, Cell Culture Media, Cell Sorting and Recovery, Flow Cytometry, Fluid Management, Industrial Microbiology, Fleet Management and Laboratory Data Software, Laboratory Filtration and Purification, Live Cell Imaging and Analysis, Pipetting, Process Chromatography, Process Filtration, Protein Analysis, among others.

Its services have mainly scientific applications, collaborating with biopharmaceutical manufacturing, Life science research, Infectious disease study, Regenerative medicine, Vaccine development, Cell and gene therapy, Pharmaceutical compliant weighing, Virus quantification, Food drinking, Medical device quality control, Oncology, Immunology, Neuroscience, Antibody discovery, Small molecule discovery, Virology and quality control industries, Food Beverage, Medical Device Quality Control, Oncology, Immunology, Neuroscience, Antibody Discovery, Small Molecule Discovery, Virology and Quality Control and Applied Industries, accelerating time-to-market with cost-saving production platforms.